S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
NYSEAMERICAN:OGEN

Oragenics (OGEN) Stock Forecast, Price & News

$2.80
-0.04 (-1.41%)
(As of 12:28 PM ET)
Compare
Today's Range
$2.80
▼
$2.80
50-Day Range
$2.94
▼
$4.18
52-Week Range
$2.60
▼
$17.40
Volume
741 shs
Average Volume
14,710 shs
Market Capitalization
$7.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

OGEN stock logo

About Oragenics (NYSEAMERICAN:OGEN) Stock

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Price History

OGEN Stock News Headlines

September 27, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Oragenics (NYSEAMERICAN:OGEN)
September 21, 2023 | americanbankingnews.com
Oragenics (NYSEAMERICAN:OGEN) Coverage Initiated by Analysts at StockNews.com
September 27, 2023 | Micro-Cap Stock Trader (Ad)
Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 7, 2023 | finance.yahoo.com
Oragenics, Inc. Announces Private Placement
June 5, 2023 | finance.yahoo.com
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
March 29, 2023 | finance.yahoo.com
Oragenics to Participate in the World Vaccine Congress Washington
March 14, 2023 | finance.yahoo.com
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
March 8, 2023 | finance.yahoo.com
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
September 27, 2023 | Micro-Cap Stock Trader (Ad)
Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
March 1, 2023 | finance.yahoo.com
Oragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing Pact
March 1, 2023 | finance.yahoo.com
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
February 3, 2023 | financialpost.com
Oragenics, Inc. Regains Compliance with NYSE American
December 23, 2022 | finance.yahoo.com
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
December 22, 2022 | finance.yahoo.com
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
December 20, 2022 | finance.yahoo.com
Oragenics, Inc. Receives NYSE American Notice
December 19, 2022 | financialpost.com
Oragenics, Inc. Announces New Chair
October 24, 2022 | finance.yahoo.com
Oragenics to Participate in the 2022 BioFlorida Annual Conference
September 30, 2022 | benzinga.com
Oral & Dental Probiotics Market Size & Shares by 2027 | Revenue, Cost Analysis, Gross Margins, Future Inv - Benzinga
September 9, 2022 | morningstar.com
Oragenics Inc OGEN Stock Quote
September 7, 2022 | reuters.com
OGEN.P - Oragenics Inc | Stock Price & Latest News | Reuters
August 30, 2022 | reuters.com
OGEN.A - Oragenics Inc | Stock Price & Latest News | Reuters
August 24, 2022 | benzinga.com
Oragenics Announces Preliminary Toxicology Data For Intranasal COVID-19 Vaccine Candidate; Says 'N T-CoV2 - Benzinga
August 24, 2022 | businesswire.com
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate - Business Wire
August 24, 2022 | finance.yahoo.com
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
August 24, 2022 | seekingalpha.com
OGN stock on watch after early toxicology data for intranasal COVID-19 shot (NYSE:OGN) - Seeking Alpha
July 29, 2022 | marketscreener.com
ORAGENICS INC - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. - Marketscreener.com
July 8, 2022 | marketscreener.com
ORAGENICS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
See More Headlines
Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

OGEN Company Calendar

Last Earnings
8/14/2023
Today
9/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:OGEN
CUSIP
N/A
CIK
1174940
Web
www.oragenics.com
Phone
813-286-7900
Fax
813-286-7904
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,290,000.00
Net Margins
N/A
Pretax Margin
-10,347.41%
Return on Equity
-128.11%
Return on Assets
-95.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.10
Quick Ratio
7.10

Sales & Book Value

Annual Sales
$130,000.00
Price / Sales
54.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.64 per share
Price / Book
0.50

Miscellaneous

Outstanding Shares
2,540,000
Free Float
2,333,000
Market Cap
$7.11 million
Optionable
Not Optionable
Beta
0.52
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Ms. Kimberly M. Murphy (Age 60)
    Pres, CEO & Director
    Comp: $550.93k
  • Dr. Martin Handfield M.Sc. (Age 52)
    Ph.D., Chief Scientific Officer
    Comp: $264.77k
  • Ms. Janet Huffman (Age 51)
    CFO, Sec. & Treasurer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OGEN Stock - Frequently Asked Questions

How have OGEN shares performed in 2023?

Oragenics' stock was trading at $0.1051 on January 1st, 2023. Since then, OGEN shares have increased by 2,564.1% and is now trading at $2.80.
View the best growth stocks for 2023 here.

Are investors shorting Oragenics?

Oragenics saw a decrease in short interest in September. As of September 15th, there was short interest totaling 15,800 shares, a decrease of 41.7% from the August 31st total of 27,100 shares. Based on an average trading volume of 10,400 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.7% of the company's stock are sold short.
View Oragenics' Short Interest.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSEAMERICAN:OGEN) released its quarterly earnings data on Monday, August, 14th. The biotechnology company reported ($1.51) EPS for the quarter. The biotechnology company had revenue of $0.01 million for the quarter.

When did Oragenics' stock split?

Oragenics's stock reverse split on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Imunon (CLSN), Jaguar Health (JAGX), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV).

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

Who are Oragenics' major shareholders?

Oragenics' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.65%). Insiders that own company stock include Fred Telling, Joseph Hernandez, Michael O'keefe Sullivan and Robert C Koski.
View institutional ownership trends.

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $2.80.

How much money does Oragenics make?

Oragenics (NYSEAMERICAN:OGEN) has a market capitalization of $7.11 million and generates $130,000.00 in revenue each year.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The official website for the company is www.oragenics.com. The biotechnology company can be reached via phone at 813-286-7900, via email at johnm@coreir.com, or via fax at 813-286-7904.

This page (NYSEAMERICAN:OGEN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -